Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
Year-over-year net income growth rate
Latest
-30.99%
↑ 98% vs avg
Percentile
P23
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-1966.03%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -30.99% |
| Q3 2025 | -82.23% |
| Q2 2025 | 10.58% |
| Q1 2025 | -1.59% |
| Q4 2024 | -85.97% |
| Q3 2024 | 28.33% |
| Q2 2024 | -47.58% |
| Q1 2024 | -12.78% |
| Q4 2023 | -43.35% |
| Q3 2023 | -8.34% |
| Q2 2023 | -28.19% |
| Q1 2023 | 30.76% |
| Q4 2022 | -13.28% |
| Q3 2022 | 4.00% |
| Q2 2022 | 3.09% |
| Q1 2022 | 2.09% |
| Q4 2021 | 45.65% |
| Q3 2021 | -33.28% |
| Q2 2021 | -4.31% |
| Q1 2021 | 14.90% |
| Q4 2020 | -38.25% |
| Q3 2020 | 9.32% |
| Q2 2020 | -69.76% |
| Q1 2020 | -9.84% |
| Q4 2019 | 29.58% |
| Q3 2019 | -132.94% |
| Q2 2019 | -78308.13% |
| Q1 2019 | 99.97% |
| Q4 2018 | 3.30% |
| Q3 2018 | 4.49% |
| Q2 2018 | 1.13% |
| Q1 2018 | -21.94% |
| Q4 2017 | -3.97% |
| Q3 2017 | 5.71% |
| Q2 2017 | -2.58% |
| Q1 2017 | -24.64% |
| Q4 2016 | 28.87% |
| Q3 2016 | 2.35% |
| Q2 2016 | 15.27% |
| Q1 2016 | 23.47% |